Why Is GENMAB A/S ADR (GMAB) Stock Up Today?

Genmab A/S ADR (GMAB) shares surged 28.25% to $57.29 on Wednesday. The primary driver was the announcement of positive Phase III clinical trial results for its head and neck cancer treatment, Petosemtamab, which demonstrated a significant reduction in mortality risk when combined with Merck’s Keytruda.

What Happened

Genmab reported that Petosemtamab, when used in combination with Keytruda, reduced the risk of death by 50% compared to Keytruda alone. This clinical update highlighted potential new treatment standards for the disease. The stock closed at an all-time high, reflecting strong investor confidence in the medical research progress. While AlphaValue/Baader Europe recently downgraded the stock to Reduce, the market response to the trial data was overwhelmingly positive. The company discussed these Phase III cancer data points in a transcript dated October 28, 2026.

What The Data Shows

The stock’s market capitalization stands at $26.5 billion with a P/E ratio of 3.5. Trailing twelve-month revenue increased by 22.3%, and the net margin is 19.1%. The stock has a beta of 0.64 and a 52-week range of $23.62 to $45.45. Over the last eight sessions, the stock moved up 48.8%, rising from $38.50 to $57.29. On October 28, 2026, the stock printed 58 fresh 52-week highs and 2 fresh 52-week lows. Unusual options activity in the last 36 hours included five notable prints, with call premium totaling $5.6 million versus put premium of $298,000. The largest single print was $2.3 million.

What To Watch

Investors will monitor the broader coverage of the Phase III results and any subsequent analyst adjustments to price targets following the clinical update.